ViewRay Announces Conference Call for Second Quarter 2022 Financial Results to be Held After Market on August 2, 2022

Rhea-AI Summary

ViewRay, Inc. (Nasdaq: VRAY) will release its first quarter 2022 financial results on August 2, 2022, followed by a conference call at 4:30 p.m. ET. Investors can join via dial-in numbers or listen to a live webcast on the company's investor relations page. A replay will be available online for 14 days, and telephonic replays will be accessible until August 16, 2022. ViewRay specializes in MR-guided radiation therapy systems, particularly the MRIdian system, designed to enhance treatment in radiation oncology.

Positive

• Scheduled financial results call for Q1 2022 signifies transparency and investor engagement
• MRIdian system tailored for addressing specific challenges in radiation oncology demonstrates product innovation

Negative

• None.

CLEVELAND, July 19, 2022 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced today details relating to the release of its first quarter 2022 financial results.

ViewRay will hold a conference call to discuss results on Tuesday, August 2, 2022 at 4:30 p.m. ET. The dial-in numbers are (646) 307-1952 for domestic callers and (888) 672-2415 for international callers. The confirmation number is 7750966. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at http://investors.viewray.com/events-and-presentations/upcoming-events.

After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website, under "Financial Events and Webinars", for 14 days following the call. In addition, a telephonic replay of the call will be available until August 16, 2022. The replay dial-in numbers are (800) 770-2030 for domestic callers and (609) 800-9909 for international callers. Please use the conference ID number 7750966.

About ViewRay®

ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

View original content:https://www.prnewswire.com/news-releases/viewray-announces-conference-call-for-second-quarter-2022-financial-results-to-be-held-after-market-on-august-2-2022-301588810.html

SOURCE ViewRay, Inc.

FAQ

When will ViewRay announce its Q1 2022 financial results?

ViewRay will announce its Q1 2022 financial results on August 2, 2022.

What time is the conference call for ViewRay's Q1 2022 results?

The conference call for ViewRay's Q1 2022 results will be held at 4:30 p.m. ET.

How can I listen to the ViewRay Q1 2022 financial results call?

You can listen to the call via dial-in numbers or through a live webcast on ViewRay's investor relations page.

Is there a replay available for the ViewRay financial results call?

Yes, a replay will be available online for 14 days after the call and via telephonic replay until August 16, 2022.

What is the main product of ViewRay?

ViewRay specializes in the MRIdian MR-guided radiation therapy system.